Julie Locklear's guest appearances

Julie Locklear

Relentless Health Value™

Mark Cuban

Kyle Samani

David Smith

Michael Hunt

Marty Makary

Mike Rea

Laura Adams

Erik Davis

Jason Rose

Johns Hopkins

James Grant

Lisa Simpson

George Mathew

John Moore

Jennifer Miller

OwlTail

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development both on the commercial and research sides of the organization. She leverages her Masters in Business Administration and Doctorate of Pharmacy to develop and deliver strategic patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult to treat diseases leading to longer, healthier, and more productive lives. Her years of experience in global and US payer markets provides Julie with intimate knowledge of the current and evolving payer and market access landscape in the United States and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US. Julie is well published, having authored more than 30 publications in peer-reviewed journals and more than 60 peer-reviewed abstracts presented as posters at major scientific congresses. 00:00 Julie’s earlier episode - EP144 - the “prequel” to this episode. 01:45 Innovative contracting and outcomes based agreements. 02:00 Real World Data vs Real World Evidence. 03:15 The reason behind the Real World Data lag in health care. 03:35 Value-based pricing. 05:00 Who has the best information on a specific product according to who owns patient population Real World Data. 05:45 What Real World Evidence is, and how it differs from Real World Data. 06:15 How Real World Evidence stems from Real World Data. 07:20 Who hires these organizations and how they fit into the value chain. 09:10 Leveraging this data into workflows. 10:30 How pharma companies will utilize Real World Data. 13:35 Are pharma manufacturers being affected by Real World Evidence or Real World Data? 16:00 Is needing Real World Evidence becoming more prominent to US health care? 18:25 The different types of data and how that affects what sorts of conclusions various payers can come to. 21:30 The current gap for physicians at the point of care. 28:25 “Collaboration is a core skill.” 29:15 “You need to first ask around - you don’t know what you don’t know.” 30:25 “One of the most important things early on is just to listen.” 32:30 Genesis Research and their work.

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development both on the commercial and research sides of the organization. She leverages her Masters in Business Administration and Doctorate of Pharmacy to develop and deliver strategic patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult to treat diseases leading to longer, healthier, and more productive lives. Her years of experience in global and US payer markets provides Julie with intimate knowledge of the current and evolving payer and market access landscape in the United States and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US. Julie is well published, having authored more than 30 publications in peer-reviewed journals and more than 60 peer-reviewed abstracts presented as posters at major scientific congresses. 00:00 Julie’s earlier episode - EP144 - the “prequel” to this episode. 01:45 Innovative contracting and outcomes based agreements. 02:00 Real World Data vs Real World Evidence. 03:15 The reason behind the Real World Data lag in health care. 03:35 Value-based pricing. 05:00 Who has the best information on a specific product according to who owns patient population Real World Data. 05:45 What Real World Evidence is, and how it differs from Real World Data. 06:15 How Real World Evidence stems from Real World Data. 07:20 Who hires these organizations and how they fit into the value chain. 09:10 Leveraging this data into workflows. 10:30 How pharma companies will utilize Real World Data. 13:35 Are pharma manufacturers being affected by Real World Evidence or Real World Data? 16:00 Is needing Real World Evidence becoming more prominent to US health care? 18:25 The different types of data and how that affects what sorts of conclusions various payers can come to. 21:30 The current gap for physicians at the point of care. 28:25 “Collaboration is a core skill.” 29:15 “You need to first ask around - you don’t know what you don’t know.” 30:25 “One of the most important things early on is just to listen.” 32:30 Genesis Research and their work.

EP174: Real World Data vs Real World Evidence, Especially for Pharma, With Julie Locklear From Genesis Research

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development both on the commercial and research sides of the organization. She leverages her Masters in Business Administration and Doctorate of Pharmacy to develop and deliver strategic patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult to treat diseases leading to longer, healthier, and more productive lives. Her years of experience in global and US payer markets provides Julie with intimate knowledge of the current and evolving payer and market access landscape in the US and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US. Dr. Locklear is well published, having authored &gt;30 publications in peer-reviewed journals and &gt;60 peer-reviewed abstracts presented as posters at major scientific congresses. 00:00 Innovation in Pharma. 04:00 “Improving patient outcomes is the goal.” 04:50 The key elements to a Value-Based contract. 05:15 “The Payer is going to need to be able to collect data.” 06:00 Look at available literature. 07:30 “Success really just means ability and feasibility.” 09:10 Review the efficacy and effectiveness of a drug. 10:00 Advice for barriers Julie has encountered. 13:00 Looking at adherence over time before looking at the actual outcome. 17:45 Patient Outcomes that matter. 18:50 The accelerating pace of Value-Based agreements. 20:30 “The right drug for the right patient at the right time.” 24:45 “The number is much larger than what you’re seeing in the public domain.” 25:00 Two examples of these Value-Based contracts. 28:00 How Action Plans change for different Payers and Stakeholders.

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development both on the commercial and research sides of the organization. She leverages her Masters in Business Administration and Doctorate of Pharmacy to develop and deliver strategic patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult to treat diseases leading to longer, healthier, and more productive lives. Her years of experience in global and US payer markets provides Julie with intimate knowledge of the current and evolving payer and market access landscape in the US and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US. Dr. Locklear is well published, having authored &gt;30 publications in peer-reviewed journals and &gt;60 peer-reviewed abstracts presented as posters at major scientific congresses. 00:00 Innovation in Pharma. 04:00 “Improving patient outcomes is the goal.” 04:50 The key elements to a Value-Based contract. 05:15 “The Payer is going to need to be able to collect data.” 06:00 Look at available literature. 07:30 “Success really just means ability and feasibility.” 09:10 Review the efficacy and effectiveness of a drug. 10:00 Advice for barriers Julie has encountered. 13:00 Looking at adherence over time before looking at the actual outcome. 17:45 Patient Outcomes that matter. 18:50 The accelerating pace of Value-Based agreements. 20:30 “The right drug for the right patient at the right time.” 24:45 “The number is much larger than what you’re seeing in the public domain.” 25:00 Two examples of these Value-Based contracts. 28:00 How Action Plans change for different Payers and Stakeholders.

EP144: Value-Based Agreements - The Future of Managing Our Healthcare Ecosystem with Julie Locklear, Vice President & Head of Health Economics & Outcomes Research at EMD Serono, Inc.